## Abstract In cases of treatmentβresistant schizophrenia the combined application of antipsychotic drugs often becomes necessary. Clozapine has been combined successfully with other atypical antipsychotic drugs such as risperidone or amisulpride in the past. We report the difficult treatment of a
Reasons for non-prescription of clozapine in treatment-resistant schizophrenia
β Scribed by M. Swinton; A.G. Ahmed
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 60 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0957-9664
- DOI
- 10.1002/cbm.313
No coin nor oath required. For personal study only.
β¦ Synopsis
Background Patients in special hospitals who are suffering from schizophrenia have lengthy admissions and this is primarily as a result of poor response to standard neuroleptics. Clozapine has a specific licence for use in such cases yet a significant proportion of special hospital patients have never been exposed to clozapine. Method One third of patients in Ashworth Hospital with schizophrenia or schizoaffective psychosis who had never been prescribed clozapine were assessed using the PANSS and the NOSIE and by interviews.
Results
The main reason for non-prescription of clozapine was the likelihood of poor compliance. Conclusion Measures to increase the compliance of this group of patients could have major benefits.
π SIMILAR VOLUMES
## Abstract ## Aims Few studies have investigated the prescription patterns of clozapine in outpatients with schizophrenia in China. It is an important issue due to clozapine's high efficacy and potentially fatal side effect profile. This study examined the use of clozapine and its correlates in C
Reactive oxygen metabolites (ROM), produced by mononuclear phagocytes may participate in brain pathology. Clozapine (CLO) may modulate cell immunity, and it is also superior to conventional neuroleptics in conditions with a putative impact of oxidative damage by ROM, i.e. negative symptoms and neuro